Zura Bio (ZURA) to Post Quarterly Earnings on Thursday

Zura Bio (NASDAQ:ZURA) is expected to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Zura Bio to announce earnings of ($0.20) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 20, 2026 at 9:30 AM ET.

Zura Bio Stock Down 5.7%

NASDAQ ZURA opened at $5.63 on Tuesday. The stock has a market cap of $534.17 million, a P/E ratio of -5.17 and a beta of -0.02. The company’s 50-day simple moving average is $4.84 and its 200 day simple moving average is $5.41. Zura Bio has a twelve month low of $1.39 and a twelve month high of $7.44.

Analysts Set New Price Targets

ZURA has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research report on Monday, July 6th. Wedbush restated an “outperform” rating and issued a $15.00 target price on shares of Zura Bio in a research note on Wednesday, July 1st. Wall Street Zen raised Zura Bio from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. Finally, William Blair assumed coverage on shares of Zura Bio in a research report on Wednesday, July 8th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.75.

Institutional Investors Weigh In On Zura Bio

Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. grew its position in shares of Zura Bio by 78.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after purchasing an additional 2,052,732 shares in the last quarter. Siren L.L.C. bought a new position in shares of Zura Bio during the fourth quarter worth approximately $6,812,000. VR Adviser LLC raised its position in shares of Zura Bio by 15.4% in the fourth quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock valued at $28,008,000 after buying an additional 713,899 shares in the last quarter. Braidwell LP raised its position in shares of Zura Bio by 28.6% in the fourth quarter. Braidwell LP now owns 3,180,389 shares of the company’s stock valued at $16,665,000 after buying an additional 707,583 shares in the last quarter. Finally, Marshall Wace LLP boosted its stake in shares of Zura Bio by 228.5% in the fourth quarter. Marshall Wace LLP now owns 877,763 shares of the company’s stock valued at $4,599,000 after buying an additional 610,563 shares during the period. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.